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The nuclear receptor peroxisome-proliferation-acti-
vated receptorgamma(PPARg), a transcriptionalmas-
ter regulator of glucose and lipid metabolism, inhibits
the growth of several common cancers, including
lungcancer. In this study,weshowthat themechanism
by which activation of PPARg inhibits proliferation of
lung cancer cells is based on metabolic changes. We
found that treatment with the PPARg agonist piog-
litazone triggers a metabolic switch that inhibits pyru-
vate oxidation and reduces glutathione levels. These
PPARg-inducedmetabolic changes result in amarked
increase of reactive oxygen species (ROS) levels that
lead to rapid hypophosphorylation of retinoblastoma
protein (RB) and cell-cycle arrest. The antiproliferative
effect of PPARg activation can be prevented by sup-
pressing pyruvate dehydrogenase kinase 4 (PDK4) or
b-oxidation of fatty acids in vitro and in vivo. Our
proposed mechanism also suggests that metabolic
changes can rapidly and directly inhibit cell-cycle pro-
gression of cancer cells by altering ROS levels.
INTRODUCTION
A hallmark of cancer is the reprogramming of glucose, lipid, and
glutamine metabolism to provide energy and substrates for
biosynthesis, which are required for proliferation and survival
of transformed cells (DeBerardinis et al., 2008; Hanahan and
Weinberg, 2011; Vander Heiden et al., 2009). A classical meta-
bolic change in cancer is the increased consumption of glucose
and inhibition of pyruvate oxidation, leading to high rates of
lactate secretion even under normoxic conditions (‘‘Warburg ef-
fect’’) (Hsu and Sabatini, 2008; Koppenol et al., 2011; Warburg,
1956). More recently, glutamine has been identified as a critical650 Cell Metabolism 20, 650–661, October 7, 2014 ª2014 Elsevier Innutrient for cancer cells to replenish TCA cycle metabolites for
the biosynthesis of lipids and mitochondrial ATP production
(DeBerardinis et al., 2007; Hensley et al., 2013), complementing
the altered state of glucose metabolism.
Therapeutic strategies harnessing alteredmetabolic properties
of cancer cells are currently focused on developing specific inhib-
itors against key metabolic enzymes, such as glutaminase (Le
et al., 2012; Robinson et al., 2007; Thangavelu et al., 2012) and
PKM2 (Christofk et al., 2008; Vander Heiden et al., 2010). In prin-
ciple, the activation or inhibition of transcriptional master regula-
tors of metabolic processes presents another promising strategy
to target cancer metabolism and may achieve a more selective
response. In this vein, our group recently found that PPARg is ex-
pressed at high levels in a subset of non-small cell lung cancer
cells (Jeong et al., 2012), where its activation with thiazolidine-
diones (TZDs) causes growth inhibition both in vitro and in vivo.
Also, growth-suppressing effects of PPARg and TZDs have
been shown for a variety of other cancers (reviewed in Koeffler,
2003; Peters et al., 2012). Considering the known functions of
PPARg in orchestrating glucose and lipid metabolism (Kliewer
and Willson, 1998; Willson et al., 2001), it is conceivable that
the antitumorigenic effects of PPARg may be mediated in part
through the activation of a genetic program that affects meta-
bolism of cancer cells. Therefore, understanding the molecular
basis of the effects of PPARg activation on lung cancer cells
may also provide general mechanistic insights into the impact
of metabolic changes on cancer cell growth. In the present study,
we sought to elucidate the molecular actions of PPARg in lung
cancer cells by integrating the analysis of genomic functions of
PPARg with biochemical follow-up analyses and metabolic
profiling of changes caused by PPARg activation.
RESULTS
PPARg Regulates the Expression of Genes Implicated in
Metabolism and Proliferation in Lung Cancer Cells
To characterize the genetic program regulated by PPARg, we
analyzed the cistrome of this transcription factor and the effectsc.
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Figure 1. Characterization of the PPARg
Cistrome in Lung Cancer Cell Lines
(A) Density plots of ChIP-seq reads for PPARg-
occupied regions in NCI-H2347 and NCI-H1993
cells. The x axis depicts 2 kb 50 and 30 to the pre-
dicted peak summits (0). The y axis depicts read
coverage.
(B) De novo motif analysis for PPARg-occupied
regions. Shared PPARg occupied regions of NCI-
H2347 and NCI-H1993 were analyzed with MEME.
The two most significant motifs are shown. These
motifs have the most significant similarity to the
known PPARg::RXRA or Fos/AP1 motif, respec-
tively.
(C) Known ENCODE and JASPAR transcription
factor motif enrichment in PPARg bound regions.
Enrichment scores and p values were calculated
based on the distribution of each motif in the
genome using 75,000 simulations.
(D) PPARg binding regions near the transcription
start sites of putative PPARg target genes (PDK4
and PLIN2), as depicted in the UCSC Genome
Browser. The x axis depicts genome coordinates;
the y axis depicts ChIP-seq read density (red: NCI-
H2347, blue NCI-H1993) normalized with respect
to input reads.
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PPARg Induces ROS to Inhibit Tumorigenesisof PPARg activation by TZDs on transcription on a genome-wide
scale. For the cistrome analysis, we used chromatin immuno-
precipitation followed by deep sequencing (ChIP-seq) with
NCI-H2347 and NCI-H1993 lung adenocarcinoma cells, which
express PPARg at high levels and whose growth is inhibited by
TZDs such as pioglitazone and troglitazone (Jeong et al.,
2012). We found 2,225 regions in NCI-H2347 cells and 1,419 in
NCI-H1993 cells with a significantly increased occupancy for
PPARg (Figure 1A; Table S1 available online). Of these binding
sites, 484 were shared by both cell lines. De novo motif analysis
of the PPARg binding regions identified a canonical PPARgmotif
consisting of two direct hexanucleotide repeats with a one nucle-
otide spacer (DR1) as themost significant motif (Figure 1B; Table
S2), which is similar to the motif elicited for PPARg occupied re-
gions in mouse 3T3-L1 cells (Lefterova et al., 2008; Nielsen et al.,
2008). The second most significant motif identified by MEME is
highly similar to the AP-1 (Fos) motif, which suggests that PPARg
target genes in lung adenocarcinoma cell lines may be coregu-
lated by AP-1 transcription factors. The canonical PPARg motif
was also the most highly and significantly enriched motif when
we compared the frequency of known transcription factor motifs
in PPARg-bound regions with respect to their frequency distribu-
tion in the human genome (Figure 1C; Table S3). This analysis
identified additional enrichedmotifs of other transcription factors
such as Nrf2 (NFE2L1), Forkhead, and CEBP family proteins,
which are recruited to PPARg binding regions (Lefterova et al.,
2008). These findings demonstrate the presence of bona fide,Cell Metabolism 20, 650–66direct binding sites of PPARg in the
genome of lung cancer cells. When we
analyzed the putative PPARg target
genes (defined as genes whose transcrip-
tion start sites are within 100 kb to PPARg
occupied loci) shared by both NCI-H2347and NCI-H1993 cells (e.g., the established PPARg target genes
PDK4 and PLIN2) (Lefterova et al., 2008; Nielsen et al., 2008)
(Figure 1D) for enrichment in functional annotation categories,
we found biological processes that are relevant for known meta-
bolic functions of PPARg (Figure 2A). Importantly, we found a
highly significant enrichment for genes implicated in several as-
pects of lipid metabolism among the predicted PPARg targets.
We next combined the analysis of the PPARg cistrome with
the analysis of the transcriptional effects of PPARg activation
by TZDs. For that purpose, we performed a time course analysis
of gene expression, where we profiled the effects of pioglitazone
treatment on the transcriptome of NCI-H2347 cells after 12, 24,
and 48 hr of treatment (Figure 2B; Table S4). We identified 1,781
genes whose expression was either significantly upregulated or
downregulated at any of the three time points (adjusted p %
0.05; fold change R 2). We used k means clustering to group
genes into five clusters with similar expression profiles. For the
obtained clusters, we analyzed PPARg binding site enrichment
(Figure 2C). We found that genes in the ‘‘Early Up’’ cluster whose
expression is upregulated after 12 hr are most significantly en-
riched for PPARg target genes predicted by ChIP-seq and thus
likely present putative direct targets of PPARg. Genes whose
expression is upregulated after 24 or 48 hr were less significantly
enriched among genes with PPARg binding sites, and genes
whose expression was decreased showed the least enrichment
among PPARg direct targets, suggesting that these genes are
not directly regulated by PPARg. Next, we performed gene set1, October 7, 2014 ª2014 Elsevier Inc. 651
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PPARg Induces ROS to Inhibit Tumorigenesisenrichment analysis (GSEA) (Subramanian et al., 2005) to eluci-
date the gene programs regulated by PPARg. Among the signif-
icantly enriched gene sets (Figure 2D), we found that genes
implicated in lipid metabolism such a fatty acid beta oxidation
were among the early upregulated genes (e.g., PDK4 and
PLIN2), while genes implicated in cell-cycle progression (e.g.,
UBE2C, BUB1, PRC1, CDK2, and CDK6) were enriched among
the genes whose expression is downregulated late (after 48 hr)
and which are not enriched for PPARg target genes. Further-
more, we found genes implicated in oxidative stress response
(e.g., SOD3, CAT, andMUC1) among the genes that were upre-
gulated at later time points. Collectively, these findings suggest
that PPARg activation causes the direct and early upregulation
of genes controlling lipid metabolism.
PPARg Activation Inhibits Cell Proliferation by an
Reactive-Oxygen-Species-Dependent Mechanism
We hypothesize that the increased expression of these genes
causes a change in cancer cell metabolism, which in turn causes
oxidative stress and ultimately leads to cell-cycle arrest in G1.
Hence, there was a reduction in transcript levels for genes that
are expressed in the S and G2/M phases of the cell cycle. To
test this hypothesis, we analyzed the effects of pioglitazone
treatment on cell-cycle progression and the levels of reactive ox-
ygen species (ROS) in the lung cancer cell lines. Using DNA con-
tent analysis by fluorescence-activated cell sorting (FACS), we
found that pioglitazone treatment caused G1 arrest in both
NCI-H2347 and NCI-H1993 cells (Figures 3A and 3B) but not in
NCI-H1299 and NCI-H1395 cells (Figures S1A and S1B), which
are essentially PPARg negative (Jeong et al., 2012). The pioglita-
zone-induced cell-cycle arrest coincided with a marked reduc-
tion in the levels of phosphorylated RB in the NCI-H2347 and
NCI-H1993 cells within 24 hr of treatment (Figure 3C), but not
in the PPARg-negative NCI-H1299 and NCI-H1395 cells (Fig-
ure S1C). We found that pioglitazone-induced RB hypophos-
phorylation was PPARg dependent, as PPARg knockdown
with two independent siRNAs prevented a reduction of phos-
phorylated RB by pioglitazone in NCI-H2347 cells (Figure S1D).
Also, we observed RB hypophosphorylation when we treated
NCI-H2347 and NCI-H1993 cells with an alternative TZD, trogli-
tazone (Figure S1E). Pioglitazone treatment of NCI-H2347 cells
resulted in decreased BrdU incorporation in a time-dependent
manner (Figure S1F) but did not cause apoptosis, as PARP or
Caspase-3 cleavage (Figure S1G) were not increased. Thus, pio-
glitazone treatment appears to inhibit cell proliferation in an RB-
dependent manner without inducing apoptosis. We found that
pioglitazone treatment of the PPARg-expressing breast cancerFigure 2. Genomic Functions of PPARg in Lung Cancer Cell Lines
(A) Concept map of PPARg targets predicted by ChIP-Seq. p values for enrichmen
to construct a network of significantly enriched signatures (FDR cut-off 1%). Th
intensity correlates with the significance of enrichment between two signature se
(B) Time course analysis of gene expression for pioglitazone treatment. Heat ma
gene expression (cut-off: fold changeR 2 and adjusted p value% 0.05) after 12
using Euclidean distance metric. Several genes are shown as examples for diffe
PRC1, CDK2, and CDK6).
(C) Enrichment for PPARg direct targets in different gene expression clusters. C
PPARg direct targets as predicted by ChIP-seq was calculated for each cluster
(D) GSEA for pioglitazone-regulated genes. Hierarchical clustering of normalize
represented in pioglitazone regulated genes.
Cellcell lines HCC-1954 and HCC-1187 (but not of the PPARg-nega-
tive breast cancer cell lines T-47D and HCC-1143) also resulted
in RB hypophosphorylation (Figure S1H), which suggests that
our findings are applicable to other major cancer types.
Next, we tested if treatment of NCI-H2347 cells with H2O2
caused RB hypophosphorylation and found that low micromolar
concentrations of H2O2 (>5 mM) caused a dose-dependent
decrease in the levels of phosphorylated RB (Figure 3D). To
analyze the impact of PPARg activation on ROS levels, we
used the fluorescent ROS probe DCFDA for FACS (Figure 3E)
and found that pioglitazone markedly increased ROS levels in
PPARg-positive NCI-H2347 (Figure 3F) and NCI-H1993 cells
(Figures S2A and S2B) but not in the PPARg-negative NCI-
H1299 and NCI-H1395 cells (Figures S2C–S2F). Likewise, piogli-
tazone markedly increased ROS levels in the PPARg-positive
HCC-1954 and HCC-1187 breast cancer cells (Figures S2G–
S2J) but not in the PPARg-negative T-47D and HCC-1143 cells
(Figures S2K–S2N). The increase in ROS levels upon pioglita-
zone treatment could be rescued both by treatment with the
antioxidant N-acetylcysteine (NAC) (Figure 3G) or PPARg knock-
down by siRNAs (Figures S2O–S2R). Furthermore, we found
ROS levels increased when we treated NCI-H2347 and NCI-
H1993 cells with troglitazone (Figures S2S–S2V).
The above findings suggested that PPARg activation causes
an increase in both ROS levels and RB hypophosphorylation.
To corroborate this hypothesis, we performed two experiments.
First, we tested if antioxidant treatment could prevent RB hypo-
phosphorylation after pioglitazone treatment in PPARg-express-
ing cells. We found that NCI-H2347 cells cotreated with NAC or
with another antioxidant, vitamin C, showed no decrease in
phosphorylated RB levels upon pioglitazone treatment (Fig-
ure 3H). Likewise, NAC prevented RB hypophosphorylation by
pioglitazone in HCC-1954 and HCC-1187 breast cancer cells
(Figure S1I). Second, we tested if increased ROS levels were
required for the growth inhibition observed for TZDs in vivo
(Jeong et al., 2012). For this purpose, we tested the effects of
NAC on pioglitazone-mediated inhibition of NCI-H2347 tumor
xenograft growth. We found that NAC cotreatment significantly
mitigated the antitumorigenic effects of pioglitazone (p = 1 3
104) (Figure 3I).
To pinpoint the mechanistic link between increased ROS
levels and RB hypophosphorylation, we tested if active dephos-
phorylation of RB by the RB-dephosphorylating enzyme protein
phosphatase 2A (PP2A) (Alberts et al., 1993; Avni et al., 2003)
was required for the effect of pioglitazone on RB phosphoryla-
tion. We found that low nanomolar concentrations of okadaic
acid, which achieves selective and effective inhibition of PP2A,t between gene signature sets were calculated (hypergeometric test) and used
e node size corresponds to the number of genes in a signature set; the edge
ts.
p of log2-tranformed fold changes of 1,781 genes with significantly differential
, 24, or 48 hr of pioglitazone treatment. Hierarchical clustering was performed
rentially expressed genes (PDK4, SOD3, CAT, PLIN2, MUC1, UBE2C, BUB1,
lusters defined by k means clustering and the significance of enrichment for
(hypergeometric test).
d enrichment scores for gene sets that are significantly (FDR % 0.05) over-
Metabolism 20, 650–661, October 7, 2014 ª2014 Elsevier Inc. 653
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Figure 3. PPARgActivation Inhibits Cell Pro-
liferation by a ROS-Dependent-Mechanism
(A and B) DNA content analysis of NCI-H2347 (A)
and NCI-H1993 (B) cells after 24 hr of treatment
with pioglitazone (Pio) or vehicle (DMSO) indicates
a G1 arrest upon PPARg activation.
(C) Pioglitazone treatment causes a decrease in the
levels of phosphorylated RB in both NCI-H2347
and NCI-H1993 cells within 24 hr.
(D) Hydrogen peroxide treatment causes a
decrease in the levels of phosphorylated RB in NCI-
H2347 within 24 hr.
(E–G) Pioglitazone treatment causes an increase in
ROS levels in NCI-H2347 cells. FACS with DCFDA
was performed after 12 hr treatment with vehicle
(DMSO) (E) or pioglitazone (F) or pioglitazone and
NAC (G). Note that the increase in ROS levels was
completely blocked by cotreatment with NAC.
(H) NAC and vitamin C prevent the reduction in
phosphorylated RB levels by pioglitazone in NCI-
H2347 cells after 24 hr of treatment.
(I) Tumor growth inhibition by pioglitazone in vivo is
ROS dependent. Mice xenografted with NCI-
H2347 cells were treated upon appearance of tu-
mors with pioglitazone, DMSO (vehicle), NAC, or a
combination of pioglitazone and NAC (i.p.) every
other day beginning on day 23 after cell injection.
Error bars represent SEM.
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PPARg Induces ROS to Inhibit Tumorigenesisprevented the increase in dephosphorylated RB after pioglita-
zone treatment (Figure S1J), suggesting that increased ROS
levels activate PP2A catalytic activity.
To further validate the specificity and characterize the effects
of TZDs on the growth of PPARg-expressing tumors, we gener-
ated NCI-H2347 cell lines that stably express two independent
shRNAs targeting PPARg (shPPARG-1 and shPPARG-2,
achieving 70% PPARg knockdown) (Figure 4A) and a non-tar-
geting shRNA (shNT) as negative control. We found that the
growth of NCI-H2347 tumors with stable PPARg knockdown
was not inhibited by pioglitazone treatment in vivo (Figure 4B).
We further characterized the underlying cause of pioglitazone-
mediated inhibition of tumor growth by analyses of xenograft tu-
mor cell proliferation (Ki-67 staining) and apoptosis (TUNEL
staining) (Figure 4C). We found that pioglitazone treatment
dramatically reduced the percentage of Ki-67 positive (i.e.,
proliferating cells) in the shNT (p = 0.0045) but not in the
shPPARG-1 and shPPARG-2 tumors (Figure 4D) (p > 0.05) and
had no statistically significant effect on the percentage of
apoptotic cells in either tumor (Figure 4E) (p > 0.05). Collectively,
these findings suggest that PPARg causes metabolic changes
that result in increased levels of ROS, which ultimately lead to
active RB hypophosphorylation and thus inhibition of cancer
cell proliferation.654 Cell Metabolism 20, 650–661, October 7, 2014 ª2014 Elsevier Inc.PDK4 and b-Oxidation Are Required
for the Effects of Pioglitazone on
ROS Levels and RB Phosphorylation
In order to identify metabolic regulators
responsible for the antitumorigenic effects
of PPARg activation, we analyzed the
functions of genes whose expression
was upregulated early by pioglitazone inour gene expression time course analysis. Among these genes,
we found pyruvate dehydrogenase kinase 4 (PDK4) as the most
highly upregulated direct PPARg target gene. Using quantitative
RT-PCR analysis, we found a 3.1-fold increase in PDK4 tran-
script levels in NCI-H2347 cells after 3 hr of pioglitazone treat-
ment, which further increased to more than 10-fold higher levels
after 12 hr (Figure 5A). PDK4 is a regulatory kinase that phos-
phorylates and thereby inhibits pyruvate dehydrogenase. Thus,
PDK4 inhibits pyruvate oxidation and was shown to mediate
the metabolic switch from glucose oxidation to fatty acid oxida-
tion in normal tissues (Andrews et al., 1998; Holness et al., 2000;
Hue and Taegtmeyer, 2009; Strand et al., 2012). Interestingly,
upregulation of PDK4 expression was previously shown to inhibit
cell proliferation of MCF-10A mammary epithelial cells (Grassian
et al., 2011). Importantly, the same study found that PDK4
expression is markedly downregulated in many common solid
tumors, including lung and breast cancer, suggesting that
PDK4 may cause metabolic changes that inhibit tumor cell pro-
liferation. We did not observe increased expression of any of the
other three pyruvate dehydrogenase kinase genes (PDK1,PDK2,
and PDK3) upon pioglitazone treatment (Figure 5B). In order to
test the role of PDK4 in the induction of oxidative stress and
RB hypophosphorylation by TZDs, we analyzed the effects of
PDK4 knockdown by siRNAs or inhibition with the pyruvate
A B
C D
E
Figure 4. The Antitumorigenic Effect of Pioglitazone In Vivo Is Caused by Inhibition of Cell Proliferation and Is PPARg Dependent
(A) PPARg mRNA expression in NCI-H2347 cells stably expressing shNT (negative control), shPPARG-1, or shPPARG-2. PPARg transcript levels were deter-
mined by quantitative RT-PCR using B2M as a calibrator (n = 3; error bars represent SD).
(B) Mice xenografted with NCI-H2347 shNT, shPPARG-1, and shPPARG-2 cells were treated upon appearance of tumors with DMSO (vehicle) or pioglitazone
every other day beginning on day 25 after cell injection. Error bars represent SEM. n = 10 for all treatment groups. Growth of the shNT tumors was inhibited by
pioglitazone treatment (p < 1 3 105), but no such effect was observed for the shPPARG-1 and shPPARG-2 tumors (p > 0.05).
(C–E) Tumors were obtained at the end of the treatment course and stained for Ki-67, TUNEL, and DNA (propidium iodide) (scale bar is 10 mm) (C). For quan-
tification of Ki-67 positivity (D) and TUNEL positivity (E), two microscopic fields containing at least 100 cells each were analyzed for each treatment group. Error
bars represent SD.
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Figure 5. PDK4 and b-Oxidation Are Required for the Effects of Pioglitazone on ROS Levels and RB Phosphorylation
(A and B) PDK4mRNA expression rapidly increases upon pioglitazone treatment (A), but expression of PDK1, PDK2, and PDK3mRNA is not increased after 24 hr
of pioglitazone treatment (B). PDK1, PDK2, PDK3, and PDK4 transcript levels in NCI-H2347 cells were determined by quantitative RT-PCR using B2M as a
calibrator for a pioglitazone treatment time course (A) or after 24 hr of treatment (B) (n = 3; error bars represent SD).
(C–G) PDK4 knockdown by siRNA prevents the decrease in phosphorylated RB (C) and the increase in ROS levels ([D]–[G]) upon pioglitazone treatment.
NCI-H2347 cells were transfected with two siRNAs targeting PDK4 or a non-targeting siRNA (siNT); after 48 hr the cells were treated with vehicle or pioglitazone
for 24 (C) or 12 hr ([D]–[G]). Then the cells were analyzed by immunoblotting (C) or stained with DCFDA and assayed by FACS ([D]–[G]).
(legend continued on next page)
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Figure 6. Tumor Growth Inhibition by Pioglitazone In Vivo Requires
PDK Activity and Fatty Acid Oxidation
(A and B) Mice xenografted with NCI-H2347 cells were treated upon appear-
ance of tumors with DMSO (vehicle), pioglitazone, DCA (A), trimetazidine (B), a
combination of pioglitazone and DCA (A), or pioglitazone and trimetazidine (B)
(i.p.) every other day beginning on day 25 after cell injection. Error bars
represent SEM. n = 10 for all treatment groups. Both DCA and trimetazidine
suppress the growth-inhibiting effects of pioglitazone (p < 1 3 105).
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PPARg Induces ROS to Inhibit Tumorigenesisdehydrogenase kinase inhibitor dichloroacetate (DCA) on ROS
levels and RB phosphorylation. We found that PDK4 knockdown
(Figure S3A) reversed the effects of pioglitazone on RB phos-
phorylation (Figure 5C) and ROS levels (Figures 3D–3G) in NCI-
H2347 and HCI-H1993 cells (Figures S3B and S3E–S3H), as
did inhibition by DCA (Figures 5H–5K, S3C, and S3I–S3L).
Next, we tested whether fatty acid oxidation was required for
the increased ROS levels and RB hypophosphorylation by
TZDs. For that purpose, we used trimetazidine, an inhibitor of
acetyl-coenzyme A acyltransferase 2, which catalyzes the termi-(H–K) Cotreatment with the PDK inhibitor DCA prevents the decrease in phosph
treatment. NCI-H2347 cells were treated with vehicle, pioglitazone, DCA, or piog
immunoblotting (H) or stained with DCFDA and assayed by FACS ([I]–[K]).
(L–O) Cotreatment with the b-oxidation inhibitor trimetazidine prevents the decre
pioglitazone treatment. NCI-H2347 cells were treated with vehicle, pioglitazone, t
the cells were analyzed by immunoblot (L) or stained with DCFDA and assayed b
Cellnal step of the b-oxidation cycle. This compound prevented RB
hypophosphorylation by pioglitazone (Figure 5L and S3D) and
the increase of ROS levels (Figures 5M–5O and S3M–S3P) by
pioglitazone in NCI-H2347 and NCI-H1993 cells. We tested
whether pioglitazone treatment affected mitochondrial super-
oxide generation directly using the superoxide fluorescent
FACS probe MitoSOX. We observed no effect of pioglitazone
on mitochondrial super oxide generation using antimycin A and
rotenone as positive controls (Figures S3Q–S3T). We note that
inhibition of NADPH oxidase, which is one major source of
ROS by apocynin, prevented the increase in ROS levels by pio-
glitazone but also caused a slight reduction of ROS levels
without pioglitazone treatment (Figures S3U–S3X).
To test the relevance of PDK4 and fatty acid oxidation on tu-
mor growth inhibition by PPARg activation in vivo, we analyzed
the effects of DCA (Figure 6A) and trimetazidine (Figure 6B) in
NCI-H2347 xenograft experiments. We found that both com-
pounds suppressed the growth-inhibiting effects of pioglitazone,
which indicates a critical role of PDK4 and fatty acid oxidation in
the antitumorigenic effects of PPARg activation. Collectively,
these findings suggest that the upregulation of PDK4, a key regu-
lator of glucose and fatty acid utilization, is necessary for the
increase in ROS levels that ultimately leads to RB hypophos-
phorylation and tumor growth arrest.
PPARg Activation Alters Glucose and Glutamine
Metabolism in NCI-H2347 Cells to Culminate in
Suppressed Glutathione Abundance
To pinpoint the metabolic effects of PPARg activation in cancer
cells, we applied a suite of assays designed to interrogate key
nodes of metabolic activity. Consistent with the known function
of PDK4 in limiting pyruvate oxidation, examination of tissue
culture medium revealed enhanced glucose consumption and
lactate secretion in pioglitazone-treated cells (Figure 7A).
Furthermore, culture with [U-13C]glucose (Figure 7B) revealed a
suppressed production of citrate molecules (Figure 7C) and
other TCA cycle metabolites (Figure 7D) containing two
glucose-derived carbons (m+2), indicative of reduced PDH
contribution to the acetyl-CoA pool. We next tested whether
metabolism of glutamine, the predominant source of glutamate,
was altered by pioglitazone. For this purpose, we pretreated
cancer cells with pioglitazone for 6 or 12 hr prior to adding
[U-13C] glutamine to the medium and followed the time course
of labeling in the glutamate pool. Pioglitazone reduced the con-
version rate of glutamine to glutamate (Figure 7E). Since gluta-
mate is required for the synthesis of glutathione (GSH), a central
component of cellular ROS detoxification, we tested whether
pioglitazone affected the levels of GSH. We found that pioglita-
zone treatment resulted in a marked decrease of both reduced
and total GSH levels (Figure 7F, S4A, and S4B), which mirrored
the effects of glutaminase inhibition by BPTES, consistent with
an overall reduction in GSH biosynthesis, as would be predictedorylated RB levels (H) and the increase in ROS levels (I-K) upon pioglitazone
litazone and DCA for 24 (H) or 12 hr ([I]–[K]). Then the cells were analyzed by
ase in phosphorylated RB levels (L) and the increase in ROS levels (M-O) upon
rimetazidine, or pioglitazone and trimetazidine for 24 (L) or 12 hr ([M]–[O]). Then
y FACS ([M]–[O]).
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demonstrate that pioglitazone markedly reduced the flux from
[U-13C] glutamine in the medium to intracellular GSH within
12 hr of treatment and also mirrored the effects of glutaminase
inhibition by BPTES (Figure S4C). Also, we found that inhibition
of fatty acid oxidation with trimetazidine prevented the reduction
of glutamate synthesis from glutamine (Figure S4D). When
considered together with our other observations, these results
suggest that the metabolic changes induced by PPARg activa-
tion impair glutaminolysis, reducing levels of glutamate and
GSH. According to thismodel, the reduction in GSH levels dimin-
ishes the capacity of the cancer cells to detoxify ROS. To cor-
roborate this hypothesis, we tested if glutaminase inhibition or
glutamine withdrawal inhibition would have similar effects in
NCI-H2347 cells as pioglitazone treatment. The glutaminase in-
hibitor BPTES also suppressed both reduced and total levels of
GSH, and combining pioglitazone with BPTES enhanced these
effects (Figure 7F). Also, we found that glutamine withdrawal re-
sulted in a marked increase of ROS levels within 12 hr (Figures
7G and 7H) and led to a time-dependent decrease of phosphor-
ylated RB levels (Figure 7I). Likewise, glutaminase inhibition with
BPTES caused upregulation of ROS levels (Figures 7J–7M),
which was suppressed by NAC (Figures S4E–S4H), led to RB hy-
pophosphorylation (Figure 7N), which was prevented by cotreat-
ment with NAC (Figure S4I) and resulted in a marked inhibition of
the growth of xenograft tumors in vivo (Figure S4J). Thus, gluta-
minase inhibition phenocopies essentially all effects of pioglita-
zone treatment, which supports our mechanistic model for the
effects of PPARg activation on cancer cell metabolism and cell
proliferation.
DISCUSSION
Tumor-suppressive functions have been proposed for PPARg
and its agonists in a variety of common cancers such as breast,
colorectal, and lung cancer (Koeffler, 2003; Peters et al., 2012).
For lung cancer, activation of PPARg with TZDs was shown to
be effective in inhibiting tumor growth of PPARg-expressing hu-
man cancer cells in vitro and in vivo (Jeong et al., 2012). Impor-
tantly, combination of TZDs with platinum-based chemotherapy
in mouse models of lung adenocarcinoma (Girnun et al., 2008)
was shown to be highly effective in reducing tumor growth,Figure 7. PPARg Activation Alters Glucose and Glutamine Metabolism
(A)Glucoseconsumptionand lactate secretion in vehicle andpioglitazone (Pio)-trea
(B) Isotope tracing diagram illustrating the supply of carbon from glucose to the TC
unlabeled carbon (12C). Abbreviations: PDH, pyruvate dehydrogenase; PDK4, py
(C and D) Mass isotopomer distribution for citrate in vehicle and pioglitazone-trea
plus additionalmass units from 13C.m+2 fraction of additionalmetabolites related
(E) Time-dependent production of [U-13C]glutamate in control and pioglitazone-t
independent culture.
(F) GSH abundance in control cells and in cells treated with pioglitazone, BPTES,
cultures. *p < 0.05; **p < 0.005.
(G and H) Glutamine depletion causes a rapid increase in ROS levels. NCI-H2347
glutamine in the medium, stained with DCFDA, and assayed by FACS.
(I) Glutamine depletion causes a decrease in phosphorylated RB levels. NCI-H234
glutamine in the medium.
(J–M) Glutaminase inhibition by BPTES causes an increase in ROS levels. NCI-H2
BPTES and pioglitazone (M), and stained with DCFDA and assayed by FACS.
(N) Glutaminase inhibition with BPTES causes a decrease in phosphorylated R
pioglitazone and BPTES for 24 hr.
Celland upregulation of PPARg expression (and its target genes)
has been linked to the antitumorigenic effects of Myc oncogene
ablation in a lung adenocarcinoma mouse model (Soucek et al.,
2013). In this vein, we found that high expression of PPARg in
early stage lung adenocarcinomas predicts longer overall and/
or progression-free survival in independent patient cohorts (Fig-
ures S4A–S4C). Collectively, these observations suggest an anti-
tumorigenic role for PPARg in lung adenocarcinoma.
Several mechanisms have been proposed for growth inhibition
of PPARg and TZDs (Koeffler, 2003; Peters et al., 2012), but
despite the established role of PPARg as a key regulator of
glucose and fatty acid metabolism in normal tissue, specific
changes in cancer metabolism have not been proposed previ-
ously as a key mechanism for the antitumorigenic actions of
PPARg. Our findings show that PPARg activation causes
changes to glucose, fatty acid, and glutamine metabolism that
ultimately result in ROS-mediated RB hypophosphorylation,
which can be prevented either by suppressing the PPARg target
PDK4 or by inhibiting b-oxidation. Thus, we propose a mecha-
nism by which PPARg-induced metabolic changes elicit direct
effects on cell-cycle progression. Importantly, our study demon-
strates an essential role of ROS in thismetabolic regulation of cell
proliferation and thus highlights a key role of ROS in the integra-
tion of metabolism and proliferation. Furthermore, we establish a
proof of principle that this pathway may be therapeutically tar-
geted with FDA-approved antidiabetic drugs such as pioglita-
zone and troglitazone. An altered redox state has long been
observed in cancer cells, making transformed cells vulnerable
to further increases in ROS levels and highly dependent on
ROS detoxification systems (Cairns et al., 2011; Trachootham
et al., 2009). In this context, our findings suggest that modulating
glucose, lipid, and glutamine metabolism with nuclear receptor
ligands, alone or in combinationwith existing therapies, may pro-
vide an avenue for the development of novel cancer treatment
strategies.EXPERIMENTAL PROCEDURES
Cell Culture
NCI-H2347 and NCI-H1993 cells were cultured in RPMI with 5% fetal bovine
serum and incubated at 37C at 5% CO2. For all experiments, cells were
seeded one day prior to treatment.in NCI-H2347 Cells to Culminate in Suppressed GSH Abundance
tedNCI-H2347cells.Dataare theaverageandSDof three independentcultures.
A cycle. Blue circles are 13C originating from [U-13C]glucose. Open circles are
ruvate dehydrogenase kinase-4; aKG, a-ketoglutarate, OAA, oxaloacetate.
ted cells cultured with [U-13C]glucose (C). Isotopomers are shown as mass (m)
to the TCA cycle (D). Data are the average andSDof three independent cultures.
reated cells cultured with [U-13C]glutamine. Each time point is derived from an
or pioglitazone and BPTES. Data are the average and SD of three independent
cells were grown for 12 hr in the presence (Gln+) (G) or absence (Gln) (H) of
7 cells were grown for 1, 2, 4, 6, 12, or 24 hr in the presence (+) or absence () of
347 cells were treated for 12 hr with vehicle (J), pioglitazone (K), BPTES (L), or
B levels. NCI-H2347 cells were treated with vehicle, pioglitazone, BPTES, or
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We generated PPARg-LAP BAC transgenic NCI-H2347 and NCI-H1993 cell
lines using the BAC-transgenesis approach to perform ChIP as previously
described (Hua et al., 2009; Kittler et al., 2013; Poser et al., 2008). Barcoded li-
braries of ChIP and input DNAwere generatedwith the SOLiD Fragment Library
Barcoding Kit (Applied Biosystems), and 35-nt single-end reads were gener-
ated with the SOLiD4 HQ system (Applied Biosystems). PPARg-bound regions
were identified as genomic regions with a significant read enrichment and
binding peak profile in the PPARg reads over the input reads by using the
Model-based Analysis of ChIP-Seq (MACS) (Poser et al., 2008) software tool
(v.1.4.2) with 1% FDR. De novo motif discovery analysis for shared PPARg-
bound regions was performed with the Multiple EM for Motif Elicitation
(MEME) software tool (Bailey et al., 2006). We analyzed the enrichment of
known transcription factormotifs by determining the frequency of knownmotifs
in PPARg-bound regions and for 75,000 random sets of the same sample size
by using Motif Scanner (Aerts et al., 2003). We performed pathway enrichment
analysis on shared PPARG target genes in NCI-H2347 and NCI-H1993 cells.
Gene sets used for this analysiswere obtained fromMerico et al. (2010). Enrich-
ment p values were calculated using hypergeometric test, and significantly en-
riched pathways (FDR% 1%) were used to construct an enrichment map.
Quantitative PCR and Microarray Analysis
Total DNA-free RNA was prepared and used for quantitative real time PCR us-
ing SYBR Green. Quantification was performed with the comparative CT
method (DDCT). Microarray analysis was performed with the Illumina Human
HT12v4.0 Expression Beadchip (Illumina, Inc.). Linear models for microarray
data (LIMMA) (Smyth, 2004) was used to identify genes that showed significant
expression changes between the pioglitazone treated and vehicle samples for
each time point (cut-off: adjusted p < 0.05 and log2-fold change ofR 1 and%
1). Clustering analysis was performed as hierarchical clustering with
Euclidean distance metric and ‘‘agglomerative average’’ method, or centroid
based clustering (k means clustering). To determine the enrichment of gene
sets at the top or bottom of a ranked list of differentially regulated genes
upon pioglitazone treatment, we performed GSEA using the time course
expression data and a priori defined gene sets.
Cell-Cycle and ROS Level Analysis
DNA content analysis was performed by FACS of 10,000 propidium-iodide-
stained cells. Intracellular ROS andmitochondrial superoxide was detected by
FACS of 10,000 cells with ROS-sensitive fluorescent probes (DCFDA and
MitoSOX).
Xenograft Experiments
NCI-H2347 cells (23 106/site, two sites/animal) were injected subcutaneously
into both flank regions of Female athymic NOD SCID mice. When tumors
became visible, treatment (intraperitoneal [i.p.]) was started with various com-
pounds or DMSO (vehicle) every other day for a total of four to five injections.
Tumor volume was calculated as (width)3 (width)3 (length)/2, where length is
greater than width. All mouse experiments were in compliance with UT South-
western Institutional Animal Care and Use Committee (IACUC) policies.
Immunohistochemistry
Tumors harvested from anesthetized mice were processed for immunohisto-
chemistry by standard procedures. Mouse anti-sera and subsequent biotin/
streptavidin-fluorescein detection of bound primary was used for Ki-67 immu-
nolabeling. Terminal deoxynucleotidyltransferase-mediated UTP end label
(TUNEL) staining for apoptotic cells was done according to the protocol sup-
plied with DeadEnd Fluorometric TUNEL System (Promega). Apoptotic cells
were labeled with fluorescein, and the sections were counterstained with pro-
pidium iodide. Image acquisition was performed with a DM5500B fluorescent
microscope (Leica).
Metabolic Assays
For the analysis of glucose metabolism, NCI-H2347 cells were incubated with
DMSO or pioglitazone for 6 hr; medium was then replaced with medium con-
taining 25 mM [U-13C]glucose. After 6 hr of labeling, medium was removed for
glucose and lactate analysis as previously described (Yang et al., 2009). For
analysis by mass spectrometry, the cells were processed as previously660 Cell Metabolism 20, 650–661, October 7, 2014 ª2014 Elsevier Indescribed (Cheng et al., 2011). To quantify the production of 13C-glutamate
from 13C-glutamine, cells were cultured in medium containing 2mM [U-13C]
glutamine and lysed at several time points over 60 min. GSH quantitation
was performed using ultra high performance liquid chromatography. For
measuring flux of extracellular glutamine to GSH, cells were cultured in me-
dium containing 2mM [U-13C]glutamine and lysed after 6, 12, or 24 hr. The
measurement of GSH was performed using a liquid chromatography-tandem
mass spectrometry approach.
Statistical Analysis
We tested the statistical significance between tumor volumes by calculating p
values for 10,000 permutations with the compareGrowthCurves function from
the Statistical Modeling package, statmod, available from the R Project (http://
www.r-project.org). For other experiments, statistical significance was deter-
mined by a two-tailed unpaired Student’s t test. p values < 0.05 were consid-
ered statistically significant.
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